Research involving Paclitaxel

FTY720 enhances the efficacy of paclitaxel and of carboplatin in drug-resistant ovarian cancer cells

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617)

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer

Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.

Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery

A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

Cost effectiveness and tolerability of dose dense versus weekly paclitaxel chemotherapy in patients with early breast cancer: A real-world comparison.

A novel diagnostic androgen receptor gene signature links clinical outcomes and preclinical response to enzalutamide, paclitaxel or the combination in triple-negative breast cancer

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.

A novel treatment for triple-negative breast cancer using intrinsic magnetized paclitaxel.

In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia.

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein

Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma - an article in the open source journal PlosOne. German study.

Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer.

Synergistic anti-tumor activity of isochaihulactone and paclitaxel on human lung cancer cells.

E2F Inhibition Synergizes with Paclitaxel in Lung Cancer Cell Lines.

Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.

The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer.

GW24-e0802 The study of polymer-free paclitaxel-eluting stent in treatment of coronary heart disease

Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer.

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib - Chinese study

Clinical trials and progress with paclitaxel in ovarian cancer

Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results

 

This Website

Resources
Research
About Us

Get in Touch

  • Email:
    info - at - chemoth.com
  • Address:
    Chemoth. 12235 Forsythe Dr.
    Austin, TX 78759